Table 1

Patient and sample characteristics

Median age at diagnosis, y (range)60.5 (39-77)
Median age at study entry, y (range)66 (41-85)
No. men/no. women54/16
Median time from diagnosis to study entry, mo (range)62 (9-300)
Rai stage at time of analysis, no. patients
Previous therapies, no. patients*
Median tumor cell content in sample, % (range)83 (30-99)
  • * Fourteen patients have received more than one regimen.

  • Assessed by flow cytometry.

  • Other therapies included alemtuzumab, rituximab, bendamustine, and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP).